Point Biopharma will use Lantheus Medical Imaging's PyL (F-18 DCFPyL) radiopharmaceutical in its phase III clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
The multicenter, open-label, randomized clinical trial will evaluate the efficacy and safety of its novel prostate-specific membrane antigen (PSMA)-targeted radioligand radiopharmaceutical, Lu-177 PNT2002, in patients with mCRPC.
PyL, which is an investigational PSMA-targeted small-molecule PET radiopharmaceutical that aims to visualize prostate cancer, will be used to determine PSMA avidity during patient selection. In addition, it will be used to evaluate progression in a subset of patients.
Lantheus subsidiary Progenics Pharmaceuticals will supply PyL at a predetermined supply price.
